Palatin Technologies, Inc. - The Bradford Era

Press Releases

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Technologies, Inc.

April 29, 2025

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyse...

Press Releases

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc.

April 18, 2025

CRANBURY, N.J. , April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class...

Press Releases

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc.

April 14, 2025

CRANBURY, N.J. , April 14, 2025 /PRNewswire/ --Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing...

Press Releases

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin Technologies, Inc.

April 10, 2025

CRANBURY, N.J. , April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSEAmerican:PTN), a biopharmaceutical company developing ...

Press Releases

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Technologies, Inc.

April 10, 2025

CRANBURY, N.J. , April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class...

Press Releases

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Technologies, Inc.

April 1, 2025

CRANBURY, N.J. , March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class...

Press Releases

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin Technologies, Inc.

March 28, 2025

CRANBURY, N.J. , March 28, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class...